Mark Kipnes
Endocrinology, Diabetes & Metabolism · San Antonio, TXNPI 1376501965
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $22,895 of the $31,516 with a category attached, or 72.6%. It is spread thinly across 59 manufacturers, the largest accounting for just 12.9%. Reporting peaked in 2019 at $8,133 and has fallen 63.5% since, to $2,970 in 2025.
Across 1,242 payments — averaging $25.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$4K
- Novo Nordisk$4K
- Mannkind Corporation$3K
- AstraZeneca$2K
- Lilly USA, LLC$1K
- Radius Health, Inc.$1K
- plus $16K from 53 others
Across 1,321 payments — averaging $7769.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$3.2M
- Medtronic$2.1M
- Dexcom, Inc.$1.9M
- AbbVie$1.3M
- Insulet Corporation$606K
- Boehringer Ingelheim$318K
- plus $763K from 13 others
What the payments were for
- Consulting fees$5,28917%
- Speaking & faculty fees$2,1257%
- Travel & lodging$1,1954%
- Food & beverage$22,89573%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$31,516 in reported general payments places this provider in the 85th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 14 | $16,140 |
| SynthroidLevothyroxine Sodium | 17 | $1,862 |
| Ezetimibe | 21 | $488 |
| Atorvastatin Calcium | 41 | $476 |
| Rosuvastatin Calcium | 29 | $347 |
| Levothyroxine Sodium | 29 | $272 |
| Metformin Hcl ErMetformin Hcl | 20 | $243 |
| Metformin Hcl | 15 | $204 |
| Losartan Potassium | 17 | $178 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $1,110 | $16,14014 claims |
| AbbVieSynthroid | $826 | $1,86217 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
Other endocrinology, diabetes & metabolism in San Antonio
- Ralph DefronzoSan Antonio$880K
- Firas AkhrassSan Antonio$801K
- Carolina Solis-HerreraSan Antonio$600K
- Jeannie BaqueroSan Antonio$573K
- Kathleen HandsSan Antonio$223K
- Shahid AzizSan Antonio$173K
- William TrigosoSan Antonio$170K
- Lance SloanLufkin$1.7M
- Pablo MoraDallas$1.3M
- Robert HoodBeaumont$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.